Biotechnology Focus

Biotechnology Focus February 2013

Biotechnology Focus is Canada's leading authority on Canada's life science news. From biopharma and healthcare to ag-bio and clean tech, our readership includes life science professionals, C-level executives and researchers.

Issue link: http://biotechnologyfocus.uberflip.com/i/108751

Contents of this Issue

Navigation

Page 10 of 31

BUSINESS CORNER Microbix' LumiSort patent upheld in U.S. The United States Patent and Trademark Office (USPTO) has for a second time upheld all key claims of Microbix' Biosystems Inc. U.S. LumiSort patent following a second competitive challenge. The USPTO plans to issue an Ex Parte Reexamination Certificate confirming the patentability of the claims of U.S. Patent 8,004,661, Microbix' first-issued patent for LumiSort technology. Sexing Technologies, a major incumbent in livestock sperm sexing, has twice challenged the patentability of the claims, and the USPTO has again rejected its challenge. "We have maintained that the technological innovation embodied in LumiSort represents a significant advancement in sperm sexing for the livestock industry. Having overcome repeated attempts to invalidate our patent, it is clear that LumiSort is sig- nificantly different from prior art technology and satisfies the standard for patent protection. We will continue to defend and expand our LumiSort patent estate as the development program advances," commented Microbix president and CEO Vaughn Embro-Pantalony on the decision. To see this story online visit http://biotechnologyfocus.ca/microbixlumisort-patent-upheld-in-u-s/ Oncolytics shares rise as company details broader use for lead product Shares of Oncolytics Biotech Inc. climbed in January after the drug developer said its lead product Reolysin may have a broader use as a potential cancer treatment. The Canadian company released results from an early-stage study of the drug as a possible treatment of colorectal cancer that has spread. It said patients taking Reolysin in combination with a common chemotherapy regimen called Folfiri had an overall progression-free survival of 7.4 months. Progression-free survival measures the time before a disease progresses or the patient in the study dies. Oncolytics said it will continue testing the drug in colorectal cancer patients. It had presented preliminary results from the small study at a recent gastrointestinal cancers symposium in San Francisco. Reolysin is based on a common virus called the respiratory enteric orphan virus, or reovirus. To see this story online visit http://biotechnologyfocus.ca/oncolyticsshares-rise-as-company-details-broaderuse-for-lead-product/ BER BioFocus_Mar2011_OUT.indd 1 2/9/11 FOCUS 11 February 2013 BIOTECHNOLOGY10:00:13 AM

Articles in this issue

Links on this page

view archives of Biotechnology Focus - Biotechnology Focus February 2013